High-growth segments, acquisition to drive gains for Torrent Pharma

Led by the India business and rest-of-the-world markets, the company reported a robust 14.3 per cent year-on-year (Y-o-Y) growth in revenues

Strong performance in the July–September quarter of 2025–26 (FY26) and expectations of growth from launches and acquisition-led synergies led to a 6.65 per cent jump in the share price of pharmaceutical (pharma) major Torrent Pharmaceuticals. Several brokerages have upgraded the stock — currently trading at ₹3,817 — citing upward earnings estimates for 2026–27 (FY27).

 

Driven by its India business and Rest of the World markets, the company reported a robust 14.3 per cent year-on-year (Y-o-Y) increase in revenue. Torrent continues to outperform the domestic market due to its strong presence in high-growth therapeutic segments. The company posted 11.5 per cent